Market Cap | 127.17M | P/E | - | EPS this Y | 14.50% | Ern Qtrly Grth | - |
Income | -62.73M | Forward P/E | -27.75 | EPS next Y | 102.00% | 50D Avg Chg | 5.00% |
Sales | 177M | PEG | 0.02 | EPS past 5Y | - | 200D Avg Chg | 3.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | -122.20% | 52W High Chg | -39.00% |
Recommedations | 3.00 | Quick Ratio | 0.42 | Shares Outstanding | 57.32M | 52W Low Chg | 72.00% |
Insider Own | 11.70% | ROA | -17.99% | Shares Float | 50.11M | Beta | 1.70 |
Inst Own | 55.08% | ROE | - | Shares Shorted/Prior | 2.64M/2.91M | Price | 2.22 |
Gross Margin | 63.77% | Profit Margin | -35.44% | Avg. Volume | 894,158 | Target Price | 2.15 |
Oper. Margin | -25.17% | Earnings Date | Nov 1 | Volume | 368,851 | Change | 0.45% |
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
HC Wainwright & Co. | Neutral | Aug 7, 23 |
HC Wainwright & Co. | Neutral | Jul 10, 23 |
HC Wainwright & Co. | Neutral | Jun 7, 23 |
Jefferies | Hold | Jun 7, 23 |
HC Wainwright & Co. | Buy | Mar 20, 23 |
HC Wainwright & Co. | Buy | May 6, 22 |
HC Wainwright & Co. | Buy | Mar 17, 22 |
WBB Securities | Strong Buy | Feb 10, 22 |
HC Wainwright & Co. | Buy | Nov 9, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
BIGHAM MICHAEL | Exec. Chairman of th.. Exec. Chairman of the Board | Feb 02 | Option | 4.3 | 23,255 | 99,996 | 1,358,032 | 09/21/23 |
Brenner Randall B. | Chief Development &.. Chief Development & Regulatory | Aug 08 | Sell | 2.2 | 27,603 | 60,727 | 415,209 | 08/10/23 |
BIGHAM MICHAEL | Exec. Chairman of th.. Exec. Chairman of the Board | Aug 08 | Sell | 2.2 | 31,250 | 68,750 | 1,334,702 | 08/10/23 |
Haskel William M. | CLO, General Counsel.. CLO, General Counsel & Sec. | Aug 08 | Sell | 2.2 | 34,526 | 75,957 | 447,024 | 08/10/23 |
Loh Evan | CEO CEO | Aug 08 | Sell | 2.2 | 48,967 | 107,727 | 1,327,981 | 08/10/23 |
BIGHAM MICHAEL | Exec. Chairman of th.. Exec. Chairman of the Board | Dec 20 | Sell | 1.99 | 15,750 | 31,342 | 1,209,702 | 12/22/22 |
Woodrow Adam | President & Chief Co.. President & Chief Commercial | Dec 12 | Sell | 1.97 | 10,073 | 19,844 | 635,534 | 12/14/22 |
Loh Evan | CEO CEO | Dec 12 | Sell | 1.97 | 99,750 | 196,508 | 1,179,187 | 12/14/22 |
Haskel William M. | CLO, General Counsel.. CLO, General Counsel & Sec. | Dec 12 | Sell | 1.97 | 37,994 | 74,848 | 399,807 | 12/14/22 |
Brenner Randall B. | Chief Development &.. Chief Development & Regulatory | Dec 12 | Sell | 1.97 | 29,282 | 57,686 | 324,851 | 12/14/22 |
BIGHAM MICHAEL | Exec. Chairman of th.. Exec. Chairman of the Board | Dec 12 | Sell | 1.97 | 51,375 | 101,209 | 1,180,452 | 12/14/22 |
Woodrow Adam | President & Chief Co.. President & Chief Commercial | Oct 28 | Sell | 3.47 | 4,563 | 15,834 | 645,607 | 11/01/22 |
Loh Evan | CEO CEO | Oct 28 | Sell | 3.47 | 8,805 | 30,553 | 1,278,937 | 11/01/22 |
Haskel William M. | CLO, General Counsel.. CLO, General Counsel & Sec. | Oct 28 | Sell | 3.47 | 4,382 | 15,206 | 437,801 | 11/01/22 |
Brenner Randall B. | Chief Development &.. Chief Development & Regulatory | Oct 28 | Sell | 3.47 | 3,516 | 12,201 | 354,133 | 11/01/22 |
BIGHAM MICHAEL | Exec. Chairman of th.. Exec. Chairman of the Board | Oct 28 | Sell | 3.47 | 6,000 | 20,820 | 1,231,827 | 11/01/22 |
Loh Evan | CEO CEO | Aug 08 | Sell | 2.66 | 44,519 | 118,421 | 1,257,742 | 08/10/22 |
Haskel William M. | CLO, General Counsel.. CLO, General Counsel & Sec. | Aug 08 | Sell | 2.66 | 22,453 | 59,725 | 432,933 | 08/10/22 |
Brenner Randall B. | Chief Development &.. Chief Development & Regulatory | Aug 08 | Sell | 2.66 | 19,608 | 52,157 | 349,149 | 08/10/22 |
BIGHAM MICHAEL | Exec. Chairman of th.. Exec. Chairman of the Board | Aug 08 | Sell | 2.66 | 28,637 | 76,174 | 1,207,827 | 08/10/22 |
BIGHAM MICHAEL | Exec. Chairman of th.. Exec. Chairman of the Board | Dec 13 | Sell | 4.35 | 31,500 | 137,025 | 890,782 | 12/15/21 |
Brenner Randall B. | Chief Development &.. Chief Development & Regulatory | Dec 13 | Sell | 4.35 | 27,894 | 121,339 | 253,530 | 12/15/21 |
Haskel William M. | CLO, General Counsel.. CLO, General Counsel & Sec. | Dec 13 | Sell | 4.35 | 30,366 | 132,092 | 340,159 | 12/15/21 |
Loh Evan | CEO CEO | Dec 13 | Sell | 4.35 | 87,076 | 378,781 | 913,284 | 12/15/21 |
Woodrow Adam | President & Chief Co.. President & Chief Commercial | Dec 13 | Sell | 4.35 | 39,992 | 173,965 | 462,329 | 12/15/21 |
Woodrow Adam | President & Chief Co.. President & Chief Commercial | Jun 08 | Sell | 9.7 | 17,182 | 166,665 | 474,796 | 06/08/21 |
Loh Evan | CEO CEO | Dec 15 | Sell | 6.83 | 45,000 | 307,350 | 600,559 | 12/15/20 |
Woodrow Adam | President & Chief Co.. President & Chief Commercial | Dec 15 | Sell | 6.83 | 21,900 | 149,577 | 271,273 | 12/15/20 |
Haskel William M. | CLO, General Counsel.. CLO, General Counsel & Sec. | Dec 15 | Sell | 6.83 | 11,656 | 79,610 | 203,267 | 12/15/20 |
Brenner Randall B. | Chief Development &.. Chief Development & Regulatory | Dec 15 | Sell | 6.83 | 14,924 | 101,931 | 128,782 | 12/15/20 |
BIGHAM MICHAEL | Exec. Chairman of th.. Exec. Chairman of the Board | Dec 15 | Sell | 6.83 | 44,400 | 303,252 | 546,517 | 12/15/20 |
Loh Evan | CEO CEO | Nov 16 | Sell | 5.93 | 20,928 | 124,103 | 645,559 | 11/16/20 |
Brenner Randall B. | Chief Development &.. Chief Development & Regulatory | Nov 16 | Sell | 5.93 | 8,357 | 49,557 | 143,706 | 11/16/20 |
Haskel William M. | CLO, General Counsel.. CLO, General Counsel & Sec. | Nov 16 | Sell | 5.93 | 6,892 | 40,870 | 214,923 | 11/16/20 |
Woodrow Adam | President & Chief Co.. President & Chief Commercial | Nov 16 | Sell | 5.93 | 15,000 | 88,950 | 293,173 | 11/16/20 |